Surgery Websites
T32 Surgical Oncology »  Faculty Mentors »  Health Services & Implementation Science »  Leslie Wilson, PhD
Leslie Wilson, PhD

Leslie Wilson, PhD

  • Professor, Medicine and Clinical Pharmacy

Contact Information

490 Illinois Street, #32F
San Francisco, CA 94158
Phone: 415-990-1012
Fax: 415-502-0792
[email protected]
Orchid: Orchid 0000-0002-3305-8730
Open Popup
Dr. Leslie Wilson is a Professor in the Department of Medicine and the Department of Clinical Pharmacy, School of Pharmacy at the University of California, San Francisco. Prior to joining the faculty at UCSF, she was the Director of Health Economics for Miles Inc. and also for Bayer AG. Dr. Wilson received her Ph.D. in health policy and economics from the University of Maryland. Her current research focuses on economic and outcome analyses including the cost of illness and cost effectiveness analyses of cancer and specific chronic diseases (including rare diseases) and how new diagnostics, treatments, and patterns of care affect the costs and outcomes of these diseases. She also looks at the epidemiology, risks and economics of Valley Fever, and also Chagas disease and its treatment in developing countries and in the U.S. blood supply. She also looks patient preference and decision making; specifically how patients weigh risks and benefits when making on treatment choices. Dr. Wilson is working with the FDA to help incorporate patient preference into approval of devices. In addition, Dr. Wilson studies the economics of policy issues, including the effects of drug legislation within the California Workers' Compensation System, and cultural competence in California medical, dental and pharmacy schools. Dr. Wilson was instrumental in bringing health economics into the current and new pharmacy curriculum and teaches a course on decision analysis modeling and an elective and independent study on research in health economics. She is the developer and Co-Director of the Program for Pharmaceutical Economics and Policy Studies(ProPEPS) whose purpose is to organize the development of economic and policy research, teaching , and funding within the Department of Clinical Pharmacy. She works with the Department of Urology on the economic issues in treatment of prostate cancer, with the Department of Neurology on a CMS innovation grant looking at new economic models of dementia care, and with the Osher Center on the economics of integrative medicine treatments.

Dr. Wilsons's current research focuses on economic and outcome analyses, including the cost of illness and cost effectiveness analyses of cancer and specific chronic diseases (including rare diseases) and how new diagnostics, treatments, and patterns of care affect the costs and outcomes of these diseases. She is currently working with the FDA to incorporate patient preference into the approval of devices using behavioral economics discrete choice approaches. Dr. Wilson has mentored multiple post-doctoral fellows. She runs the Program for Outcomes and Pharmaceutical Economics and Policy Studies which has mentored numerous students and fellows across clinical departments, enabling them to enter clinical or policy related careers.

Trainee opportunities include participation discrete choice experiments of new approaches to cancer screening and of adherence decision for oral cancer drugs given cost information. Training in the conduct of cost-effectiveness analyses of new cancer treatments as well as new approaches to data generation in the course of care (OneSource).

Data provided by UCSF Profiles, powered by CTSI
  1. Wilson L, Gress AF, Frassetto L, Sarathy H, Gress EA, Fissell WH, Roy S. Patient Preference Trade-offs for Next-Generation Kidney Replacement Therapies. Clin J Am Soc Nephrol. 2023 Oct 06. View in PubMed
  2. Wilson L, Zheng P, Ionova Y, Denham A, Yoo C, Ma Y, Greco CM, Hanmer J, Williams DA, Hassett AL, Scheffler AW, Valone F, Mehling W, Berven S, Lotz J, O'Neill C. CAPER: patient preferences to inform nonsurgical treatment of chronic low back pain: a discrete-choice experiment. Pain Med. 2023 Aug 01; 24(8):963-973. View in PubMed
  3. Wilson L, Dohan D, Garibaldi M, Szeto D, Timmerman M, Matheny J. Prosthesis preferences for those with upper limb loss: Discrete choice study of PULLTY® for use in regulatory decisions. J Rehabil Assist Technol Eng. 2023 Jan-Dec; 10:20556683231152418. View in PubMed
  4. Weng X, Zhong L, Xiang P, Li Y, Paciorek A, Dong L, Broering J, Carroll PR, Sanda M, Wilson L. Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence. Eur J Cancer Care (Engl). 2022 Nov; 31(6):e13740. View in PubMed
  5. Wilson L, Kwok T, Ma Y, Wong J, Ho M, Ionova Y, McGrath M, Mueller MM, Gitelman SE, Irony T. Preferences for Risks and Benefits of Islet Cell Transplantation for Persons With Type 1 Diabetes With History of Episodes of Severe Hypoglycemia: A Discrete-Choice Experiment to Inform Regulatory Decisions. Transplantation. 2022 08 01; 106(8):e368-e379. View in PubMed
  6. View All Publications


Site Directory